College of Medicine, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada.
Expert Rev Clin Pharmacol. 2011 Jan;4(1):63-73. doi: 10.1586/ecp.10.133.
The metabolic syndrome is a group of abnormalities including obesity, high blood pressure, hyperinsulinemia, high blood glucose levels and hyperlipidemia that together greatly increase the risk of developing cardiovascular disease and Type 2 diabetes. Hydrogen sulfide (H(2)S) is a vasodilatory gasotransmitter mediator in the cardiovascular system, proposed as an endothelium-derived relaxing factor. A lack of H(2)S and its synthesizing enzyme, cystathionine γ-lyase, in the vasculature causes hypertension, whereas an increase in the pancreas reduces insulin secretion. Thus, research is making inroads to determine whether H(2)S is involved in the pathogenesis of the metabolic syndrome. Several laboratories are synthesizing and testing clinically used drugs that release H(2)S. Some of these compounds are being tested for effectiveness in the metabolic syndrome.
代谢综合征是一组异常的病症，包括肥胖、高血压、高胰岛素血症、高血糖水平和高血脂症，这些病症共同极大地增加了患心血管疾病和 2 型糖尿病的风险。硫化氢 (H(2)S) 是心血管系统中的一种血管舒张性气体递质介质，被认为是内皮衍生的舒张因子。血管中缺乏 H(2)S 和其合成酶胱硫醚 γ-裂解酶会导致高血压，而胰腺中 H(2)S 的增加会减少胰岛素的分泌。因此，研究正在深入探讨 H(2)S 是否参与代谢综合征的发病机制。几个实验室正在合成和测试释放 H(2)S 的临床使用药物。其中一些化合物正在测试其在代谢综合征中的有效性。
